KITLG and leukemia: Therefore, to identify some of the steps connecting SCF or MBCD stimulus to GLUT1 modulation and to highlight any potential differences, we tested the effect of two tyrosine kinase inhibitors, Imatinib mesylate, a c-kit inhibitor employed in the treatment of leukemia [29], and PP2, a potent inhibitor of the Src tyrosine kinase family [30], on glucose transport enhancement in M07e cells.